The Contrast Media Market is expected to experience a steady growth rate of 5-6% CAGR. Key drivers of this growth include innovations in imaging technologies, the rising incidence of chronic ...

The launch of Pixxoscan expands GE HealthCare’s portfolio of Magnetic Resonance Imaging (MRI) contrast agents, now offering two leading macrocyclic molecules to customers - Clariscan (gadoteric acid) ...

Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...

Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings ...